Dr. Chen Xiaoxin, Vice President of Raynovent was Invited to Attend Shenzhen International Biopharmaceutical Industry Innovation & Development Summit 2019. Time:2019.09.25Views:64Author:Raynovent Previous:Raynovent Announces Signing of Strategic Cooperation Agreement with Raffles Next:Raynovent Announces Initiation of Phase 2 Clinical Trial of ZSP1273, a Category 1 Drug Intended to Treat and Prevent Influenza A and Human Avian Influenza. News Center
